Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

FORGOTTEN HISTORY: Akouos org - The Untold Story

Crude Oil Drops Over 2%; Akouos Shares Spike Higher

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 300 points on Tuesday.

Benzinga · Oct 18, 2022

Why Akouos Shares Are Trading Sharply Higher? Here Are 36 Stocks Moving In Tuesday's Mid-Day Session

Gainers

Benzinga · Oct 18, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022

Upgrades

Benzinga · Sep 29, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Benzinga · Sep 13, 2022

Akouos: Q1 Earnings Insights

Akouos (NASDAQ:AKUS) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 12, 2022

Recap: Akouos Q4 Earnings

Akouos (NASDAQ:AKUS) reported its Q4 earnings results on Tuesday, March 29, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 29, 2022

Coverage From

Benzinga

Organisations

Charter Communications

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.